NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

Area of Science:

• Hematology and Oncology
• Immunotherapy
• Clinical Guidelines

Background:

• Relapsed/refractory B-cell lymphomas present significant treatment challenges.
• Traditional treatment paradigms are being rapidly updated by novel therapeutic agents.
• Mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL) are key subtypes.

Purpose of the Study:

• To summarize recent advancements in targeted therapies for B-cell lymphomas.
• To highlight updates to the NCCN Guidelines for FL, DLBCL, and MCL.
• To provide insights into the evolving treatment landscape for relapsed/refractory disease.

Main Methods:

• Review of novel targeted therapies including small molecule inhibitors, antibody-drug conjugates, and cellular therapies.
• Analysis of Bruton's tyrosine kinase (BTK) inhibitors' evolving role.
• Evaluation of CD19-directed therapies such as CAR T-cells and bispecific T-cell engagers.

Main Results:

• Targeted therapies have transformed the management of relapsed/refractory B-cell lymphomas.
• BTK inhibitors are increasingly important in MCL, both frontline and relapsed/refractory.
• CAR T-cell therapies and bispecific T-cell engagers offer new options for relapsed/refractory FL, DLBCL, and MCL.

Conclusions:

• Significant updates to NCCN Guidelines reflect the rapid progress in B-cell lymphoma treatment.
• Novel immunotherapies and targeted agents are becoming standard of care.
• These advancements offer improved outcomes for patients with relapsed/refractory B-cell lymphomas.